Device platform strategy and manufacturing readiness in San Diego

In combination product development, early platform decisions often do more than define the device path. They can also influence how smoothly a product scales, how reliably it can be manufactured, and how effectively more complex therapies can be translated into practical delivery solutions. 

These topics remain part of broader industry discussions, including at PFS and Injectable Drug Devices West Coast 2026, taking place June 8-10 in San Diego, USA. SHL Medical will be among the participating companies.   

As part of our showcase, we will feature Reunite, a dual-chamber cartridge autoinjector designed for lyophilized drug delivery.

Additional devices on display will include:

SHL Medical’s Senior Customer Solutions Manager, Dr. Nina Fetz will also deliver a dedicated 30-minute presentation during the event, titled “Reunite: From Complex Vial Kits to True Patient Independence.” The session will highlight how Reunite combines automated reconstitution and injection in an intuitive three-step autoinjector for lyophilized drug delivery.  

Visitors attending the event are welcome to connect with our representatives in San Diego to discuss device platform strategy and combination product development planning.